



Thanks to our Australian collaborators, NHMRC National Institute for Dementia Research and Dementia Australia.

**Sydney, Australia
Sept. 25-27, 2019
Hyatt Regency Sydney**

Wednesday, Sept. 25

8-9 a.m. Rolling registration and breakfast

9-9:25 a.m. Welcome Address
Alzheimer's Association
Dementia Australia

**Harry Johns (U.S.)
Maree McCabe (AUS)
Roberta Redman (AUS)**

National Institute for Dementia Research

Janice Besch (AUS)

9:25-9:55 a.m. Keynote
Molecular Imaging of Dementia:
Research and Clinical Application

Christopher Rowe (AUS)

Session 1: Novel Biomarkers: Volume 1

Session Leader: Donna Wilcock (U.S.)

9:55-10:15 a.m. Alpha Synuclein As Potential Pathophysiological
Marker Of Alzheimer's

Filippo Baldacci (Italy)

10:15-10:35 a.m. Retinal Imaging And Dementia: An Overview

Tien Yin Wong (Singapore)

10:35-10:55 a.m. Mapping Of Alzheimer's Retinopathy And
Predicting Disease Stage

Maya Koronyo-Hamaoui (U.S.)

10:55-11:15 a.m. Neurofilament Light And Phosphorylated Tau In
Blood As AD Biomarkers

Kaj Blennow (Sweden)

11:15-11:40 a.m. Panel of Session 1 speakers and keynote
Moderator: Donna Wilcock (U.S.)

11:40 a.m.-1 p.m. LUNCH AND POSTER VIEWING

1-2 p.m. Lightning Poster Round 1
Moderator: Cassandra Szoeker (AUS)

Session 2: Novel Biomarkers: Volume 2 (Early Detection)

Session Leader: Simon Laws (AUS)

2-2:20 p.m.	Visualizing Mitochondrial Abnormalities In Alzheimer's Models Using PET	Anna Barron (Singapore)
2:20-2:40 p.m.	Using DIAN To Identify And Stage Novel Biomarkers For Alzheimer's Disease	Peter Schofield (AUS)
2:40-3 p.m.	Plasma Amyloid Beta Biomarker: The Potential For Clinical Application	Akinori Nakamura (Japan)
3-3:20 p.m.	Plasma Biomarkers For Predicting Amyloid Beta Accumulation And Neurodegeneration In Alzheimer's Disease	Colin Masters (AUS)
3:20-3:40 p.m.	Panel of Session 2 speakers Moderator: Simon Laws (AUS)	
3:40-4:10 p.m.	BREAK	

Session 3: Therapeutics: State of the Field

Session Leader: Malu Tansey (U.S.)

4:10-4:30 p.m.	Ultrasound: Novel Treatment Modality For Neurodegenerative Diseases	Jürgen Götz (AUS)
4:30-4:50 p.m.	Use Of Amyloid Imaging In Therapeutic Trials	Victor Villemagne (AUS)
4:50-5:10 p.m.	Tau Immunotherapies	Einar Sigurdsson (U.S.)
5:10-5:30 p.m.	A Biomarker-Directed Approach To Targeting Inflammation In Alzheimer's Patients	CJ Barnum (U.S.)
5:30-5:50 p.m.	Panel of Session 3 speakers and Giulio Pasinetti (U.S.) Moderator: Malu Tansey (U.S.)	
5:50-6 p.m.	Close of Day 1	Maria Carrillo (U.S.)
6-7:30 p.m.	OPENING RECEPTION	

Thursday, Sept. 26

8-9 a.m.	Rolling registration and breakfast	
9-9:10 a.m.	Welcome of Day 2 and keynote introduction	Maria Carrillo (U.S.)
9:10-9:40 a.m.	Keynote 2: Role of Inflammation in AD/ADRD	Malu Tansey (U.S.)
9:40-10:45 a.m.	LIGHTNING POSTER SESSION Moderator: Claire Sexton (U.S.)	

10:45-10:55 a.m. Dementia Australia Maree McCabe (AUS)

10:55-11:20 a.m. BREAK

Session 4: Vascular Contributions: Adding the “V” to ATN Framework

Session Leader: Charles DeCarli (U.S.)

11:20-11:40 a.m. Plasma Exosome-Based Biomarkers Of VCID Fanny Elahi (U.S.)

11:40 a.m.-Noon CSF Biomarkers Of VCID Donna Wilcock (U.S.)

Noon-12:20 p.m. Imaging Based Biomarkers Of VCID Hanzhang Lu (U.S.)

12:20-12:40 p.m. Clinical Biomarkers Of VCID Velandai Srikanth (AUS)

**12:40-1 p.m. Panel of Session 4 speakers and keynote
Moderator: Charles DeCarli (U.S.)**

1-2:15 p.m. LUNCH AND POSTER VIEWING

2:15-2:30 p.m. Alzheimer’s Disease International Glenn Rees (AUS)

Session 5: Contributing Risk Factors – Genetics and Vascular Contributions

Session Leader: Samantha Burnham (AUS)

**2:30-2:50 p.m. Post-Stroke Cognitive Impairment From A
Global Perspectiva: Clinical Characteristics
And Risk Factors Perminder Sachdev (AUS)**

**2:50-3:10 p.m. Cognitive Aging In Urban And Rural India:
Contribution Of Vascular Risk Factors Naren Rao (India)**

**3:10-3:30 p.m. Sex Differences And Vascular Risk Factors
In Dementia Cassandra Szoeki (AUS)**

3:30-3:50 p.m. Gene Combinations And AD Risk In AIBL Simon Laws (AUS)

3:50-4:15 p.m. BREAK

4:15-4:35 p.m. SINGER: Intervention In Singapore Christopher Chen (Singapore)

4:35-4:55 p.m. ARROW: Intervention In Australia Ralph Martins (AUS)

4:55-5:15 p.m. U.S. POINTER and KHANDLE studies Rachel Whitmer (U.S.)

**5:15-5:40 p.m. Panel of Session 5 speakers
Moderator: Samantha Burnham (AUS)**

5:40-5:45 p.m. Close of Day 2 Maria Carrillo (U.S.)

Friday, Sept. 27

8-8:30 a.m.	Breakfast	
8:30-8:40 a.m.	Opening of Day 3 and keynote introduction	Rachel Whitmer (U.S.)
8:40-9:10 a.m.	Keynote 3: WHO Guidelines On Risk Reduction Of Cognitive Decline And Dementia: Implications For Researchers And Policymakers	Kaarin Anstey (AUS)

Session 6: Underrepresented Populations/Observational/Pop Studies: Volume 1

Session Leader:	Mary Sano (U.S.)	
9:20-9:40 a.m.	Late-Life Risk Factors For Cognitive Performance And Decline Around The Globe: The COSMIC Collaboration	Darren Lipnicki (AUS)
9:40-10 a.m.	Differences In The Biology Of Cognitive Impairment Within A Diverse Cohort	Charles DeCarli (U.S.)
10-10:20 a.m.	Progress In Aboriginal And Torres Strait Islander Dementia Prevention And Care Research	Kate Smith (AUS)
10:20-10:40 a.m.	<i>StepUp</i> For Dementia Research: <i>A Dementia Breakthrough, Powered By You</i>	Yun-Hee Jeon (AUS)
10:40-11:10 a.m.	BREAK AND CHECKOUT	

Session 7: Role of Psychogeriatrics in Dementia Care: Volume 2

Session Leader:	Mary Sano (U.S.)	
11:10-11:30 a.m.	ABCD: The Role Of Psychogeriatrics in Assessment And Better Care For Dementia	Henry Brodaty (AUS)
11:30-11:50 a.m.	Lifestyle Modification And Disease Stage: What The Practitioner Needs To Know	Nicola Lautenschlager (AUS)
11:50 a.m.- 12:10 p.m.	Nursing Research Integrating Technology Into Long-Term Care	Wendy Moyle (AUS)
12:10-12:35 p.m.	Panel: Session 6 and 7 speakers Moderator: Mary Sano (U.S.)	
12:35-12:45 p.m.	Closing remarks	Maria Carrillo (U.S.)
12:45 p.m.	Boxed lunch and departures	

Lightning Poster Round Presenters
Wednesday, Sept. 25
Moderator: Cassandra Szoeki (AUS)

Presenters and Topics:

Dr. Prita Asih, Australia

Elevated Plasma Soluble TREM2 In Elderly Individuals With High Neocortical Amyloid- β Load

Dr. James Doecke, Australia

Exploring CSF Biomarkers That Add Value To CSF Ab42, t-Tau And p-Tau For Correlation With β -Amyloid PET Status

Dr. Eleanor Drummond, Australia

Phosphorylated Tau Interactome In The Human Alzheimer's Disease Brain

Dr. Dhamidhu Eratne, Australia

Neurofilament Light Chain In Psychiatric And Neurodegenerative Disorders: A 'c-Reactive Protein' For The Brain

Mr. Colin Groot, Netherlands

FDG-PET Reveals Distinct Temporal And Spatial Patterns Of Hypometabolism In Cognitively-Defined Subgroups Of Typical Alzheimer's Disease

Dr. Kevin Huynh, Australia

In-Depth Lipidomic Profiling Of the Australian Imaging Biomarker And Lifestyle Flagship Study Of Aging

Dr. Louise Lavrencic, Australia

Mild Cognitive Impairment In Older Aboriginal Australians

Dr. Ramon Martinez-Marmol, Australia

Inhibition Of PI 3-Kinase p110 δ As A New Approach To Protect Against Alzheimer's Disease

Dr. Andrew McKinnon, Australia

Sleep And Circadian Functioning Relates To White Matter Micro- and Macro-Structure In Older Adults With A Lifetime History Of Depression

Dr. Peter van Wijngaarden, Australia

A Hyperspectral Retinal Imaging Biomarker Of Alzheimer's Disease

Mr. Robert Williams, Australia

The Use of Phantom Measurement To Harmonise Image Reconstruction In Florbetapir PET

Lightning Poster Round Presenters
Thursday, Sept. 26
Moderator: Claire Sexton (U.S./U.K.)

Presenters and Topics:

Ms. Karissa Barthelson, Australia

Identifying Early Molecular Changes Underlying Familial Alzheimer's Disease Due To Mutations In *SORL1*

Dr. Pierrick Bourgeat, Australia

Comparing A β -Amyloid Positivity Thresholds Using Suvr And Centiloid Across Tracers

Dr. Zac Chatterton, Australia

Peripheral Monitoring Of Neurodegeneration Using Cell-Free DNA Methylation

Dr. Carol Dobson-Stone, Australia

Identification Of A Novel Gene Causing Frontotemporal Dementia – Amyotrophic Lateral Sclerosis

Dr. R.M. Damian Holsinger, Australia

Fecal Microbiota Transplantation Improves Cognition And Significantly Reduces Amyloid Pathology In 5XFAD Alzheimer's Mice

Dr. Woojin Kim Australia

Analysis Of Frontotemporal Dementia Serum Using Lipidomics Technology

Dr. Michelle Lupton, Australia

Genetic Risk Prediction For Alzheimer's Disease And Association With Baseline Measures In The PISA Study

Dr. Morgan Newman, Australia

Biased Allele Expression And Loss Of Hypoxia Response In A Zebrafish Model Of Familial Alzheimer's Disease

Dr. Giulio Pasinetti, United States

Inhibition Of Brain Innate Immunity As Novel Therapeutic Approach In Alzheimer's Disease To Attenuate Psychological Stress Induced Dementia

Mr. Anishchal Pratap, Australia

Altered Metabolic Characteristics Of Activated Astrocytes In The 5XFAD Mouse Model Of Alzheimer's Disease

Dr. Jonathan Teo, Australia

Loss Of Sphingosine Kinase 2 In Alzheimer's Disease Impedes Amyloid Deposition But Enhances Hippocampal Volume Loss And Demyelination

Dr. Giuseppe Verdile, Australia

Relevance Of A Truncated *Presenilin 2* Transcript To Alzheimer's Disease And Neurodegeneration